Gossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Down 9.4% in October

Gossamer Bio, Inc. (NASDAQ:GOSS) saw a large decline in short interest in October. As of October 31st, there was short interest totalling 6,300,000 shares, a decline of 9.4% from the October 15th total of 6,950,000 shares. Based on an average daily trading volume, of 810,000 shares, the days-to-cover ratio is presently 7.8 days.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Gossamer Bio in a report on Monday, November 11th. Wedbush reaffirmed an “outperform” rating and set a $4.00 target price on shares of Gossamer Bio in a research report on Tuesday, August 13th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $9.20.

Hedge Funds Weigh In On Gossamer Bio

A number of institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC bought a new position in shares of Gossamer Bio during the first quarter valued at approximately $34,000. US Bancorp DE bought a new stake in shares of Gossamer Bio in the third quarter worth approximately $39,000. Choreo LLC purchased a new stake in Gossamer Bio during the second quarter valued at $46,000. GSA Capital Partners LLP purchased a new position in shares of Gossamer Bio in the third quarter worth approximately $67,000. Finally, Algert Global LLC bought a new stake in Gossamer Bio during the second quarter valued at approximately $75,000. Institutional investors own 81.23% of the company’s stock.

Gossamer Bio Stock Performance

NASDAQ:GOSS traded down $0.02 on Monday, reaching $0.72. 597,580 shares of the company’s stock were exchanged, compared to its average volume of 1,430,347. The stock has a fifty day simple moving average of $0.93 and a 200-day simple moving average of $0.87. The company has a debt-to-equity ratio of 3.64, a current ratio of 6.74 and a quick ratio of 6.74. Gossamer Bio has a 52 week low of $0.50 and a 52 week high of $1.60. The firm has a market cap of $163.17 million, a price-to-earnings ratio of -2.29 and a beta of 1.96.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04. The firm had revenue of $9.48 million for the quarter, compared to analysts’ expectations of $4.52 million. As a group, sell-side analysts predict that Gossamer Bio will post -0.28 earnings per share for the current year.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.